

# Programme

## Day 1 11th October, Tuesday

12:20-12:30	<b>Opening Remarks</b> President: Tsuneyo Mimori (Kyoto University, Japan)
12:40-13:25	<b>Luncheon Seminar 1</b> SS-LS1 <b>Current state of indirect immunofluorescence in ANA diagnostics</b> Chair : Shunichi Kumagai (Shinko Hospital, Japan) Speaker : Kai Fechner (EUROIMMUN AG, Germany) <b>Sponsored by Cosmic Corporation Co., Ltd</b>
13:35-14:00	<b>Lecture 1</b> L1 <b>MHC class II-associated neo-self antigens are novel targets for autoantibodies</b> Chair : Koichiro Ohmura (Kyoto University, Japan) Speaker : Hisashi Arase (Osaka University, Japan)
14:00-14:25	<b>Lecture 2</b> L2 <b>Is there a place for ANA pattern and titer in monitoring SLE disease activity ?</b> Chair : Edward K.L. Chan (University of Florida, USA) Speaker : Luis Eduardo C. Andrade (Universidade Federal de São Paulo, Brazil)
14:25-14:50	<b>Lecture 3</b> L3 <b>Regulatory B10 Cells Govern the Balance of Protective and Pathogenic Autoreactivities</b> Chair : Jack D. Keene (Duke University Medical Center, USA) Speaker : Thomas F. Tedder (Duke University Medical Center, USA)
14:50-15:15	<b>Lecture 4</b> L4 <b>Autoantibody maturation as a biomarker for RA development</b> Chair : Ignacio García-De La Torre (University of Guadalajara, Mexico) Speaker : Tom W. J. Huizinga (Leiden University Medical Center, The Netherlands)
15:15-16:15	<b>Poster Session I</b> P <b>*And Coffee Break</b>
16:15-18:15	<b>Symposium 1</b> <b>In corporation with the 24th Symposium on Autoantibodies and Autoimmunity</b> S1 <b>Evolving Science of Autoimmune Myopathy</b> Chair: Hitoshi Kohsaka (Tokyo Medical and Dental University, Japan) Manabu Fujimoto (University of Tsukuba, Japan)  S1-1 <b>FHL1, a novel muscle specific autoantigen in severe inflammatory myopathies</b> Ingrid E. Lundberg (Karolinska Institutet, Sweden)  S1-2 <b>Pathogenicity of muscle specific autoantibodies</b> Olivier Benveniste (Hôpital Pitié-Salpêtrière, France)  S1-3 <b>International Classification Criteria</b> Masatoshi Jinnin (Kumamoto University, Japan)  S1-4 <b>Myositis-specific (MSA) and myositis-associated antibodies (MAA) in patients with idiopathic inflammatory myopathies (IIM) from the PANLAR Myositis Study Group</b> Ignacio García-De La Torre (University of Guadalajara, Mexico)  S1-5 <b>Novel myositis-specific autoantibody</b> Yuji Hosono (Kyoto University, Japan)  S1-6 <b>Altered peripheral lymphocyte subset repertoires that reflect clinical features of dermatomyositis and polymyositis</b> Hirokazu Sasaki (Tokyo Medical and Dental University, Japan) <b>Sponsored by Medical &amp; Biological Laboratories Co., Ltd.</b>

- 18:25–19:10 Evening Seminar 1**  
**SS-ES1 Role of autoantibodies in neuropsychiatric systemic lupus erythematosus**  
 Chair : Tatsuya Atsumi (Hokkaido University, Japan)  
 Speaker : Shunsei Hirohata (Kitasato University, Japan)  
 Sponsored by Chugai Pharmaceutical Co., Ltd.

---

**19:40–21:10 Welcome Reception**

---

## Programme

### Day 2 12th October, Wednesday

- 8:00–8:45 Morning Seminar 1**  
**In corporation with the 16th Seminar for Clinical Immunology in Kyoto**  
**SS-MS1 Gut microbiota and autoimmunity**  
 Chair: Minoru Satoh (University of Occupational and Environmental Health, Japan)  
 Speaker: Sachiko Miyake (Juntendo University, Japan)  
 Sponsored by Asahi Kasei Pharma Corporation

- 
- 8:55–10:35 Symposium 2**
- S2 Germinal Center and Autoimmunity**  
 Chair: Kazuhiko Yamamoto (The University of Tokyo, Japan)  
 Tomohiro Kurosaki (Osaka University, Japan)
- S2-1 Overview of germinal center immunity**  
 Tomohiro Kurosaki (Osaka University, Japan)
- S2-2 Role of T follicular helper (T<sub>FH</sub>) in humoral immunity**  
 Masato Kubo (Tokyo University of Science, Japan)
- S2-3 Rogue Germinal Center B Cells and Autoantibody Production**  
 Robert Brink (Garvan Institute of Medical Research, Australia)
- S2-4 Divergent regulation and/or function of follicular helper and regulatory T cells in humans**  
 Carola G. Vinuesa (Australian National University, Australia)
- S2-5 Control of B cell responses by combination of regulatory cytokines**  
 Keishi Fujio (The University of Tokyo, Japan)

---

**10:35–11:00 Coffee Break**

---

- 11:00–11:40 Special Lecture 1**  
**SL1 Rheumatoid Factor as Antibody to Immune Complexes: Its Pathogenic Role in RA**  
 Chair: Joachim R. Kalden (Friedrich-Alexander University Erlangen-Nürnberg, Germany)  
 Speaker: Eng M. Tan (The Scripps Research Institute, USA)

- 
- 11:40–12:50 Oral Session I**
- Chair: Falk Hiepe (Charité-University Medicine Berlin, Germany)  
 Takao Fujii (Wakayama Medical University, Japan)
- OS1-1 Opsonization of apoptotic cells is required to generate the interferon signature in lupus**  
 Westley H. Reeves (University of Florida, USA)
- OS1-2 TCR signaling defect by ZAP70 mutation causes lupus like nephritis on C57BL/6 background**  
 Takashi Matsuo (Kyoto University, Japan)
- OS1-3 LRG promotes the differentiation of Th17 and deteriorate collagen-induced arthritis**  
 Hyun Lee (National Institute of Biomedical Innovation, Health and Nutrition, Japan)

- OS1-4 **RNA sequencing of immune cell subsets before and after biologics in rheumatoid arthritis**  
Mineto Ota (The University of Tokyo, Japan)
- OS1-5 **Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of autoimmune vasculitis**  
Masayuki Nishide (Osaka University, Japan)
- OS1-6 **Type II collagen immune complex induce granulocyte dependent augmentation of chemokines via TLR4; a possible therapeutic target in acute onset early RA**  
Johan Ronnelid (Uppsala University, Sweden)

- 13:00–13:45 **Luncheon Seminar 2**  
SS-LS2 **Pathological involvement of semaphorins in autoimmune, allergy and inflammatory diseases**  
Chair: Kazuhiko Yamamoto (The University of Tokyo, Japan)  
Speaker: Atsushi Kumanogoh (Osaka University, Japan)  
**Sponsored by Mitsubishi Tanabe Pharma Corporation**

- 13:55–14:20 **Lecture 5**  
L5 **Serum CXCL10 levels are associated with clinical manifestations and disease activity in Behçet's disease: a prospective follow-up study**  
Chair: Shinji Sato (Tokai University, Japan)  
Speaker: Yeong Wook Song (Seoul National University Hospital, Republic of Korea)

- 14:20–14:45 **Lecture 6**  
L6 **First evidence of antigen-specific plasma cell depletion in vivo by an affinity matrix**  
Chair: Westley H. Reeves (University of Florida, USA)  
Speaker: Falk Hiepe (Charité - Universitätsmedizin Berlin, Germany)

- 14:45–15:10 **Lecture 7**  
L7 **Adjuvants, lymphoma, ASIA syndrome and autoimmunity**  
Chair: Karsten Conrad (Technical University Dresden, Germany)  
Speaker: Yehuda Shoenfeld (Sheba Medical Center, Israel)

- 15:10–16:10 **Poster Session II**  
P **\*And Coffee Break**

- 16:10–17:50 **Symposium 3**  
S3 **Autoimmune Neurological Disorders**  
Chair: Takashi Yamamura (National Center of Neurology and Psychiatry, Japan)  
Angela Vincent (University of Oxford, UK)
- S3-1 **From neuromuscular junction to brain: the role of autoantibodies to membrane proteins**  
Angela Vincent (University of Oxford, UK)
- S3-2 **Anti-LGII antibodies in anti-VGKC complex antibodies**  
Osamu Watanabe (Kagoshima University, Japan)
- S3-3 **Regulation of CNS inflammation**  
Francisco J. Quintana (Harvard Medical School and The Broad Institute, USA)
- S3-4 **Aquaporin-4 antibody in neuromyelitis optica spectrum disorders**  
Kazuo Fujihara (Fukushima Medical University, Japan)
- S3-5 **Anti-MOG antibody in CNS demyelinating diseases**  
Ichiro Nakashima (Tohoku University, Japan)

- 18:00–18:45 **Evening Seminar 2**  
SS-ES2 **Clinical aspects and pathogenic roles of autoantibodies in systemic sclerosis**  
Chair: Manabu Fujimoto (University of Tsukuba, Japan)  
Speaker: Masataka Kuwana (Nippon Medical School, Japan)  
**Sponsored by Taisho Toyama Pharmaceutical Co., Ltd.**

# Programme

## Day 3 13th October, Thursday

8:00–8:45	<b>Morning Seminar 2</b>	
	<b>SS-MS2</b>	<b>Treatments of rheumatoid arthritis in future</b> Chair: Tsuneyo Mimori (Kyoto University, Japan) Speaker: Yoshiya Tanaka (University of Occupational and Environmental Health, Japan) <b>Sponsored by AYUMI Pharmaceutical Corporation</b>
8:55–9:20	<b>Lecture 8</b>	
	<b>L8</b>	<b>Molecular control of T cell function in immunity</b> Chair: Luis Eduardo C. Andrade (Universidade Federal de São Paulo, Brazil) Speaker: Chen Dong (Tsinghua University, China)
9:20–10:00	<b>Special Lecture 2</b>	
	<b>SL2</b>	<b>Control of immune responses by regulatory T cells</b> Chair: Marvin J. Fritzler (University of Calgary, Canada) Speaker: Shimon Sakaguchi (Osaka University, Japan)
10:00–10:25	<b>Coffee Break</b>	
10:25–11:10	<b>Sponsored Seminar 1</b>	
	<b>SS-SS1</b>	<b>Recent advances in antiphospholipid antibodies</b> Chair: Takao Koike (NTT Sapporo Medical Center, Japan) Speaker: Tatsuya Atsumi (Hokkaido University, Japan) <b>Sponsored by UCB Japan Co. Ltd.</b>
11:10–11:30	<b>3rd ICAP Report</b>	
	<b>ICAP</b>	<b>The challenge and importance of international standardization of ANA testing</b> Edward K.L. Chan (University of Florida, USA)
11:40–12:25	<b>Luncheon Seminar 3</b>	
	<b>SS-LS3</b>	<b>Janus kinase inhibitors are launched in rheumatoid arthritis therapy</b> Chair: Takao Fujii (Wakayama Medical University, Japan) Speaker: Masao Tanaka (Kyoto University, Japan) <b>Sponsored by Pfizer Japan Inc.</b>
12:35–13:55	<b>Oral Session 2</b>	
	Chair:	Manfred Herold (Medical University of Innsbruck, Austria) Minoru Satoh (University of Occupational and Environmental Health, Japan)
	<b>OS2-1</b>	<b>Quantifying post-transcriptional RNA regulons in immune cells</b> Jack D. Keene (Duke University Medical Center, USA)
	<b>OS2-2</b>	<b>Reducing false positive ANA rates by determination of anti-DFS70 antibodies</b> Karsten Conrad (Technical University Dresden, Germany)
	<b>OS2-3</b>	<b>Anti-DNA antibodies are internalized into live cells via cell surface DNA</b> Siriphone Virachith (Tokyo Medical and Dental University, Japan)
	<b>OS2-4</b>	<b>B2-glycoprotein I / HLA class II complexes are novel autoantigens in antiphospholipid syndrome</b> Kenji Tanimura (Osaka University, Japan)
	<b>OS2-5</b>	<b>Clinical correlation of Novel Autoantibodies in Primary Sjögren's Syndrome</b> Long Shen (University at Buffalo, USA)
	<b>OS2-6</b>	<b>Nuclear Dense Fine Speckled ANA Pattern is Associated with a Normal Laboratory Profile</b> Andressa Mathias (Fleury Medicine and Health Laboratories, Brazil)

**13:55-14:40 Sponsored Seminar 2**

**SS-SS2 Updates of abatacept, a T-cell co-stimulation modulator**  
Chair: Yoshinari Takasaki (Juntendo University, Japan)  
Speaker: Tsutomu Takeuchi (Keio University, Japan)

**Sponsored by Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd.**

---

**14:40-15:00 Closing Ceremony**

President: Tsuneyo Mimori (Kyoto University, Japan)

---

**15:10-16:40 The 3rd International Consensus on Antinuclear Antibody Pattern (ICAP) Executive Committee Meeting**

\*ICAP Executive Members only

---

**October 11th, Tuesday 15:15–16:15**  
**Poster Session 1**

**1. ANA and Assays (1)**

- P1-1 ANA testing: the clinicians' point of view**  
Manfred Herold (Medical University of Innsbruck, Austria)
- P1-2 Automated evaluation of ANA patterns with EUROPattern meets the ICAP guideline**  
Kai Fechner (EUROIMMUN AG, Germany)
- P1-3 Evaluation of Crithidia luciliae IFT can be reliably automated with EUROPattern**  
Kai Fechner (EUROIMMUN AG, Germany)
- P1-4 Evaluation of modified Crithidia luciliae IIFT for detection of anti-dsDNA antibodies**  
Kai Fechner (EUROIMMUN AG, Germany)
- P1-5 ANA screening on DFS70-knockout HEp-2 cells in a routine setting**  
Werner Klotz (Medical University of Innsbruck, Austria)
- P1-6 ANA testing on HEp-2 cells and antigen-coated microparticles including DFS70**  
Rico Hiemann (Brandenburg University of Technology Cottbus-Senftenberg, Germany)
- P1-7 Automated digital classification of HEp-2 pattern according to ICAP classification tree**  
Rico Hiemann (Brandenburg University of Technology Cottbus-Senftenberg, Germany)
- P1-8 Novel Engineered HEp-2 Substrate and its Impact on DFS70 and ANA Screening Algorithm**  
Kishore Malyavantham (Immco Diagnostics, USA)
- P1-9 Proposal of an International Standard for Anti-DFS70/LEDGFp75 Antibodies**  
Alessandra Dellavance (Fleury Laboratories, Brazil)

**2. ANA and Assays (2)**

- P2-1 Harmonization of HEp-2 cell assays using anti-cell pattern description proposed by ICAP**  
Nadja Roeber (Technical University Dresden, Germany)
- P2-2 Differentiation of immunofluorescence pattern of anti-Ro/SS-A antibody positive sera**  
Nadja Roeber (Technical University Dresden, Germany)
- P2-3 Performance comparison of the HELMED<sup>®</sup> Blot Module and HELIA<sup>®</sup> using AESKUBLOTS<sup>®</sup> ANA-17 Pro**  
Aaron Lerner (AESKU. Diagnostics GmbH & Co. KG, Germany)
- P2-4 MULTICENTER STUDY OF ANA VALIDATION BY IFA IN THE AUTOMATED HELIOS<sup>®</sup> AND HELMED<sup>®</sup>**  
Aaron Lerner (AESKU. Diagnostics GmbH & Co. KG, Germany)
- P2-5 IMMUNOFLUORESCENCE STUDIES FOR THE SPECIFIC DIAGNOSTICS OF MYASTHENIA GRAVIS BY IFA IN THE AUTOMATED HELIOS<sup>®</sup>**  
Aaron Lerner (AESKU. Diagnostics GmbH & Co. KG, Germany)
- P2-6 An effective method to identify autoantigens expressed on the cell surface: SARF**  
Tsuyoshi Shirai (Tohoku University, Japan)

**3. Rheumatoid Arthritis - Basic**

- P3-1 Gut microbiota from rheumatoid arthritis patients induce severe arthritis in SKG mice**  
Yuichi Maeda (Osaka University, Japan)

- P3-2 STS-2 (Suppressor of TCR signaling-2) suppresses collagen-induced arthritis in mice**  
Namiko Okabe (Kyoto University, Japan)
- P3-3 INVOLVEMENT OF REGULATORY T CELLS AND MICRORNAS IN REGULATION OF COLLAGEN-INDUCED ARTHRITIS IN MICE TREATED WITH IL-2/ANTI-IL-2 IMMUNE COMPLEXES**  
Yuichi Yokoyama (Hyogo College of Medicine, Japan)
- P3-4 Crucial involvement of citrullinated proteins and ACPA in peptide GPI-induced arthritis**  
Hoshimi Kawaguchi (University of Tsukuba, Japan)
- P3-5 Neo-self IgG/HLA-DR complexes are involved in RA susceptibility as autoantibody targets**  
Hui Jin (Osaka University, Japan)
- P3-6 The proportion of regulatory T cells in rheumatoid arthritis; comparison of the results from different definition of regulatory T cells**  
Takayoshi Morita (Osaka University, Japan)
- P3-7 Adhesion molecules on synovial fibroblast promote cytokine production from CD4+T cells**  
Masato Mori (Kyoto University, Japan)
- P3-8 Co-localization of citrullinated proteins, PAD4 and ACPAs in CD68+ cells in RA synovium**  
Naoto Umeda (University of Tsukuba, Japan)

#### 4. Rheumatoid Arthritis - Clinical

- P4-1 Clinical significance of anti-mutated citrullinated vimentin antibodies in RA patients**  
Nozomi Ishigooka (Kyoto University, Japan)
- P4-2 Prediction of Onset of Rheumatoid Arthritis with ACPA Screening in 11758 Asymptomatic Middle-Aged Women**  
Masato Okada (St. Luke's International University Hospital, Japan)
- P4-3 Anti-CCP titers in patients with elderly onset rheumatoid arthritis (RA): Analysis using a nationwide RA database in Japan (NinJa)**  
Tetsuji Sawada (Tokyo Medical University, Japan)
- P4-4 Radiographic thymus alteration associates with clinical feature in autoimmune diseases**  
Okinori Murata (Keio University, Japan)
- P4-5 Anti-carbamylated protein antibody is detectable in various collagen vascular diseases**  
Shuichiro Nakabo (Kyoto University, Japan)
- P4-6 Intracellular methotrexate polyglutamates is regulated by gene polymorphisms of a folate-related enzyme**  
Tatsuhiko Yamamoto (Toho University, Japan)
- P4-7 Autoantibodies against CD74 - A new diagnostic marker for Spondyloarthritis (SpA)**  
Aaron Lerner (AESKU.Diagnostics GmbH & Co. KG, Germany)
- P4-8 Elevated MMP-3 levels in early RA patients sera with Borrelia Antibodies**  
Aaron Lerner (AESKU.KIPP Institute, Germany)

#### 5. Intestinal Immunity and Diseases

- P5-1 The ulcerative colitis susceptibility gene RNF186 regulates intestinal homeostasis**  
Kosuke Fujimoto (Osaka University, Japan)
- P5-2 Leucine-rich  $\alpha$ 2-glycoprotein (LRG) enhances colonic inflammation by increasing leukocyte adhesion to TGF- $\beta$ -stimulated endothelium**  
Takashi Mishima (National Institute of Biomedical Innovation, Health and Nutrition, Japan)

- P5-3 New markers for celiac disease: anti-neo-epitope human and microbial transglutaminases**  
Aaron Lerner (AESKU.KIPP Institute, Germany)
- P5-4 COMPARISON OF THE RELIABILITY OF CELIAC DISEASE SEROLOGY TO REFLECT INTESTINAL DAMAGE**  
Aaron Lerner (AESKU.KIPP Institute, Germany)
- P5-5 TISSUE/MICROBIAL TRANSGLUTAMINASE NEO-EPITOPES SHOW SIMILAR IMMUNO-EPITOPES IN CELIACS**  
Aaron Lerner (AESKU.Diagnostics GmbH & Co. KG, Germany)
- P5-6 3-D STRUCTURES OF HUMAN AND MICROBIAL TRANSGLUTAMINASES COMPLEXED TO GLIADIN ARE SIMILAR**  
Aaron Lerner (AESKU.KIPP Institute, Germany)
- P5-7 ANTI ENTEROCYTE AUTOANTIBODIES IN CELIAC DISEASE**  
Aaron Lerner (AESKU.KIPP Institute, Germany)
- P5-8 GLUTEN IMMUNOLOGICAL SIDE EFFECTS ARE DETRIMENTAL TO HUMAN HEALTH**  
Aaron Lerner (AESKU.KIPP Institute, Germany)
- P5-9 THE INTESTINE AS PRIMARY SITE FOR POST-TRANS MODIFICATION IN SYSTEMIC AUTOIMMUNE DISEASE**  
Aaron Lerner (AESKU.KIPP Institute, Germany)
- P5-10 Peripheral organs' autoimmunity is highly connected to the intestinal ecosystem's events**  
Aaron Lerner (AESKU.KIPP Institute, Germany)
- P5-11 Evaluation of liver tissue as substrate for detection of endomysium antibodies**  
Kai Fechner (EUROIMMUN AG Labormedizinische Diagnostika AG Dassow, Germany)

## 6. Skin and Liver Diseases

- P6-1 Autoimmune CD8 T cell-mediated interface dermatitis is regulated by Langerhans cells**  
Noriko Kubota (University of Tsukuba, Japan)
- P6-2 Perforin is essential for induction of keratinocytes death in a murine model of autoimmune mucocutaneous disease with interface dermatitis**  
Akimasa Saito (University of Tsukuba, Japan)
- P6-3 A multivariant profile ELISA for one-step diagnostics of autoimmune bullous dermatoses**  
Mende Miriam (EUROIMMUN AG, Germany)
- P6-4 IgG4-positive cells in the affected skin of alopecia areata**  
Takaharu Ikeda (Wakayama Medical University, Japan)
- P6-5 Diversity of humoral responses to the centromere proteins in chronic liver diseases**  
Takashi Himoto (Kagawa Prefectural University of Health Sciences, Japan)
- P6-6 Multiplex autoantibody detection for autoimmune liver diseases and autoimmune gastritis**  
J. Vanderlocht (Maastricht University Medical Center, The Netherlands)
- P6-7 Jade-2 is a novel component of autoantigenic 'rod and ring' intracellular structures**  
S. John Calise (University of Florida, USA)



**October 12th, Wednesday 15:10-16:10**  
**Poster Session 2**

**7. Myopathies and Autoantibodies**

- P7-1 Myositis-specific and myositis-associated autoantibodies in patients with myositis**  
Shusaku Nakashima (Kagawa University, Japan)
- P7-2 Comparison of Prognosis in Interstitial Lung Disease Between Polymyositis/ Dermatomyositis Patients with Anti-Jo-1 Antibody and Anti-EJ Antibody**  
Shinji Sato (Tokai University, Japan)
- P7-3 The analysis of inflammatory myopathies complicated with interstitial lung disease with anti-Jo-1 antibody**  
Yumiko Sugiyama (Yokohama City University, Japan)
- P7-4 Anti-aminoacyl-tRNA synthetases (ARS) antibody seems to be associated with the severity of muscular manifestation and alveolar-endothelial damages**  
Ayako Kawano (University of Miyazaki, Japan)
- P7-5 Anti-MDA5 Antibody Positive Juvenile Dermatomyositis with Hemophagocytic Syndrome (a case report and literature review)**  
Yoshihiro Hishitani (Hyogo Prefectural Kobe Children's Hospital, Japan)
- P7-6 Nailfold vascular findings of anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis**  
Kazuhiro Komura (Tsuruga Hospital, Japan)
- P7-7 Predictive factors of poor prognosis and utility of plasmaexchange in anti-MDA5(+)dermatomyositis with interstitial lung disease under immunosuppressive therapy**  
Mirei Shirakashi (Kyoto University, Japan)
- P7-8 In situ expression of transcriptional intermediary factor-1  $\gamma$  (TIF-1  $\gamma$ ) in patients with cancer-associated myositis (CAM)**  
Hiroko Kadota (Nippon Medical School, Japan)
- P7-9 Clinical features and prognosis in anti-SRP and anti-HMGCR necrotizing myopathy**  
Shigeaki Suzuki (Keio University, Japan)
- P7-10 Interstitial Lung Disease in Patients with Anti-Signal Recognition Particle Antibodies**  
Keiichiro Kadoba (Kyoto University Hospital, Japan)
- P7-11 Presence of anti-cN-1A (Mup44, NT5c1A) IgG is specific for Sporadic Inclusion Body Myositis**  
Mende Miriam (EUROIMMUN AG, Germany)
- P7-12 Clinical Significance of Cyclic Citrullinated Peptide-specific Antibody and Rheumatoid Factor in Patients with Polymyositis/Dermatomyositis**  
Shinji Sato (Tokai University, Japan)
- P7-13 Autoantibodies to Su/Argonaute 2 in Japanese patients with inflammatory myopathy**  
Mariko Ogawa-Momohara (Nagoya University, Japan)

**8. Systemic Lupus Erythematosus**

- P8-1 Antibody to Ribonuclease-H2 is a novel autoantibody specifically recognized in SLE; Importance of intramolecular epitope spreading for autoantibody production**  
Kazuhiisa Nozawa (Juntendo University, Japan)
- P8-2 Association of anti-TPI antibodies with aseptic meningitis in patients with NPSLE**  
Shuzo Sato (Fukushima Medical University, Japan)

- P8-3 Antibodies to Microtubule Associated Protein-2 in the Cerebrospinal Fluid are a Useful Diagnostic Biomarker for Neuropsychiatric Systemic Lupus Erythematosus**  
Kazuhisa Nozawa (Juntendo University, Japan)
- P8-4 Novel autoantigens associated with lupus nephritis**  
Sachiko Araki (Ehime University, Japan)
- P8-5 Cleaved Form of Osteopontin in Urine as a Clinical Marker of Lupus Nephritis**  
Koji Kitagori (Kyoto University, Japan)
- P8-6 Role of Mucosal-associated Invariant T (MAIT) Cells In Lupus Dermatitis**  
Goh Ebata Murayama (Juntendo University, Japan)
- P8-7 Angioimmunoblastic T-cell lymphoma with autoimmune hemolytic anemia and thrombocytopenia mimicking SLE**  
Mikiko Hashimoto Iguchi (Kyoto Medical Center, Japan)
- P8-8 A patient-derived autoimmune IgG monoclonal anticardiolipin antibody that binds to beta 2 glycoprotein domain I but not to total beta 2 glycoprotein I molecule**  
Kenji Oku (Hokkaido University, Japan)
- P8-9 Clinical Analysis of 12 Pediatric Patients of Antiphospholipid Syndrome with Pulmonary Embolism**  
Hongmei Song (Peking Union Medical College Hospital, China)

#### 9. Systemic Sclerosis and Sjögren's Syndrome

- P9-1 Genetic mutation of phospholipase D4 disturbs the homeostasis and immunological tolerance of B cells in mice**  
Shuji Akizuki (Kyoto University, Japan)
- P9-2 Clinical and serological features of anti-centromere antibody-positive systemic sclerosis in Chinese patients**  
Jiucun Wang (Fudan University, China)
- P9-3 Anti-activin type IIB receptor intracellular domain (ACVRIIB-in) Ab may relate the cause of Systemic sclerosis (SSc) with anti-topoisomerase-I antibody (ATA)**  
Michihito Katayama (Osaka University, Japan)
- P9-4 Serum Calprotectin levels in Japanese patients with diffuse and limited systemic sclerosis**  
Gary L Norman (Inova Diagnostics, USA)
- P9-5 Biomarker of YKL-40 for the Presence of Interstitial Pneumonia and Pulmonary Arterial Hypertension in Systemic Sclerosis**  
Tetsuya Furukawa (Hyogo College of Medicine, Japan)
- P9-6 Efficacy of autologous stem cell transplantation in the treatment of systemic sclerosis**  
Toshio Odani (Hokkaido University, Japan)
- P9-7 Regenerating Gene Protein as a Novel Autoantigen in the Pathogenesis of Sjögren's Syndrome**  
Takashi Fujimoto (Nara Medical University, Japan)
- P9-8 Serum ganglionic acetylcholine receptor antibodies in patients with Sjögren's syndrome**  
Akihiro Mukaino (Kumamoto University Hospital, Japan)
- P9-9 Alteration of clinical course by Immunosuppressants in children with positive anti-Ro antibodies and with chronic nonspecific complaints**  
Yasuhiko Itoh (Nippon Medical School, Japan)

## 10. ANCA and Vasculitis

- P10-1 Detection of ANCA: a multicenter EUVAS evaluation of the value of indirect immunofluorescence versus antigen-specific immuno-assays**  
Jan Damoiseaux (Maastricht University Medical Center, The Netherlands)
- P10-2 Effects of urea treatment on the antineutrophil anticytoplasmic antibodies (ANCA)**  
Estela Motta (Hospital Dr. Oscar Alende, Argentina)
- P10-3 Myeloperoxidase/HLA class II complexes as targets for autoantibodies in microscopic polyangiitis**  
Ryosuke Hiwa (Kyoto University, Japan)
- P10-4 PR3-ANCA in children and adolescents with inflammatory bowel disease**  
Nadja Roeber (Technical University Dresden, Germany)
- P10-5 DNA-BOUND LACTOFERRIN IS THE MAJOR TARGET FOR P-ANCA IN ULCERATIVE COLITIS**  
Kai Fechner (EUROIMMUN AG, Germany)
- P10-6 IL-12p40 in Pathophysiology of Takayasu Arteritis**  
Toshiki Nakajima (Kyoto University, Japan)
- P10-7 Three cases of varied size vessel vasculitis; Large vessel vasculitis with small or medium vessel involvement**  
Michihiro Kono (Hokkaido University, Japan)

## 11. Innate Immunity and Diseases

- P11-1 Regulation of autoimmune responses through TRIM-regulated precision autophagy and secretion**  
Tomonori Kimura (Osaka University, Japan)
- P11-2 Histone H1: a novel alarmin-like mediator and molecular target for immune regulation**  
Toshiaki Nakano (Chang Gung University, Taiwan)
- P11-3 Extracellular linker histone H1 deteriorates IgE-mediated allergic hypersensitivity**  
Takashi Fujimura (Hiroshima University, Japan)
- P11-4 Anti-nuclear antibody positive rate in familial Mediterranean fever patients in Kagawa university hospital**  
Miharu Izumikawa (Kagawa University, Japan)
- P11-5 A case of drug hypersensitivity mimicking adult-onset still's disease**  
Tokutaro Tsuda (St. Luke's International Hospital, Japan)

## 12. Miscellaneous Diseases

- P12-1 Leucine rich  $\alpha$ -2 glycoprotein promotes lung fibrosis by modulating TGF- $\beta$  signaling**  
Hiromi Honda (National Institute of Biomedical Innovation, Health and Nutrition, Japan)
- P12-2 Anti-GM-CSF/MHC class II complex antibody in autoimmune pulmonary alveolar proteinosis**  
Yoshimasa Hamano (Osaka University, Japan)
- P12-3 The clinical significance of autoantibody-producing CD180-lacking plasmablasts in systemic autoimmune and immune-based inflammatory disorders**  
Syuichi Koarada (Saga University, Japan)
- P12-4 The role of novel lipid mediators in connective tissue diseases**  
Isao Murakami (Kyoto University, Japan)

**P12-5 The Effect of Quality Indicator Monitoring for Glucocorticoid-Induced Osteoporosis**

Masato Okada (St. Luke's International University Hospital, Japan)

**P12-6 Is hormone replacement therapy an effective treatment for arthralgia in post-/ peri-menopausal women?**

**Two case reports from an ongoing trial**

Kiyomitsu Miyachi (Keigu Clinic, Japan)